JP2022546861A5 - - Google Patents
Info
- Publication number
- JP2022546861A5 JP2022546861A5 JP2022515704A JP2022515704A JP2022546861A5 JP 2022546861 A5 JP2022546861 A5 JP 2022546861A5 JP 2022515704 A JP2022515704 A JP 2022515704A JP 2022515704 A JP2022515704 A JP 2022515704A JP 2022546861 A5 JP2022546861 A5 JP 2022546861A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061710A JP2025102940A (ja) | 2019-09-10 | 2025-04-03 | マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898469P | 2019-09-10 | 2019-09-10 | |
| US62/898,469 | 2019-09-10 | ||
| PCT/US2020/049986 WO2021050580A1 (en) | 2019-09-10 | 2020-09-09 | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061710A Division JP2025102940A (ja) | 2019-09-10 | 2025-04-03 | マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546861A JP2022546861A (ja) | 2022-11-09 |
| JPWO2021050580A5 JPWO2021050580A5 (https=) | 2023-06-16 |
| JP2022546861A5 true JP2022546861A5 (https=) | 2023-06-16 |
Family
ID=74866002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515704A Pending JP2022546861A (ja) | 2019-09-10 | 2020-09-09 | マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用 |
| JP2025061710A Pending JP2025102940A (ja) | 2019-09-10 | 2025-04-03 | マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061710A Pending JP2025102940A (ja) | 2019-09-10 | 2025-04-03 | マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12466838B2 (https=) |
| EP (1) | EP4027999B1 (https=) |
| JP (2) | JP2022546861A (https=) |
| CN (1) | CN114401720A (https=) |
| CA (1) | CA3150267A1 (https=) |
| WO (1) | WO2021050580A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202302597A (zh) * | 2021-03-10 | 2023-01-16 | 美商米拉蒂醫療公司 | 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途 |
| WO2022240802A1 (en) | 2021-05-10 | 2022-11-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of sitravatinib salts and processes for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101125932B1 (ko) | 2006-12-06 | 2012-03-22 | 아이디유엔 파마슈티칼즈, 인코포레이티드 | (3ｓ)-3-［ｎ-(ｎ'-(2-ｔｅｒｔ-부틸페닐)옥사밀)알라니닐］아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태 |
| BRPI0816064B8 (pt) * | 2007-08-29 | 2021-05-25 | Methylgene Inc | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica |
| US8907091B2 (en) * | 2007-08-29 | 2014-12-09 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| US20180237378A1 (en) * | 2015-08-19 | 2018-08-23 | Sandoz Ag | Asymmetric Bisamidation of Malonic Ester Derivatives |
| EP3740491A1 (en) * | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN109384799B (zh) * | 2018-11-12 | 2020-07-14 | 深圳海王医药科技研究院有限公司 | 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物 |
-
2020
- 2020-09-09 EP EP20862121.9A patent/EP4027999B1/en active Active
- 2020-09-09 CA CA3150267A patent/CA3150267A1/en active Pending
- 2020-09-09 JP JP2022515704A patent/JP2022546861A/ja active Pending
- 2020-09-09 US US17/762,713 patent/US12466838B2/en active Active
- 2020-09-09 CN CN202080063504.1A patent/CN114401720A/zh active Pending
- 2020-09-09 WO PCT/US2020/049986 patent/WO2021050580A1/en not_active Ceased
-
2025
- 2025-04-03 JP JP2025061710A patent/JP2025102940A/ja active Pending